Universal! Swiss-Tyring bio-allogeneic immunocellular therapy products have been approved clinically

Screenshot Source: CDE Official Website Ruitron Bio is a wholly owned subsidiary of Zhejiang Ruishun Bio, which specializes in the development and clinical application of generic (foreign) RC1012 injection products for recurring acute myeloid leukemia (AML), and is an innovative biopharmaceutical enterprise with the mission of providing treatment or cure for leukemia patients.
press release, the RC1012 injection is a globally innovative allogeneic immunocellular therapy developed by Swisstron Bio.
the cell therapy is prepared from the outer hemoplification of healthy donors and is rich in CD3-CD4-CD8-T (Double Negative T, DNT) cell substations.
DNT cells, also known as bi-negative T-cells, are T-cell subtypes that express CD3 molecules in normal human exoenvironomic blood, but do not express CD4 and CD8 molecules, and have a stronger specific effect on the activity and longer body duration of AML tumor cells than NK cells, and are a general-purpose T-cell therapy with great hope for treating a variety of clinical tumors.
Ruitron bio-disclosure data show that due to the high heterogeneity of AML tumor cells, no tumor antigens can be specific to attack AML cells, so the clinical application of CAR-T technology in AML is limited, and the multi-target specific killing of AML cell function of DNT cells is to make up for its defects.
trial data initiated by researchers who have completed the study show that RC1012 injections have good safety and predictable effectiveness in treating patients with relapsed and difficult-to-treat acute myeloid leukemia.
According to the press release, the purpose of the approved registered clinical trial is to further verify the safety and effectiveness of the product's treatment of r/r AML in registered clinical trials, to speed up the normative clinical development of the drug, and to be approved as soon as possible for the treatment of patients with relapsed AML after chemotherapy or bone marrow transplantation.
: The first isomer immunocellular therapy product RC1012 injection clinical trial developed by Ruitron Bio has been approved by the State Drug Administration of China. Retrieved Nov 19, 2020, from s.2. Swiss bioRC1012 injections were accepted by the NMPA clinical trial. Retrieved Aug 27, 2020, from Source: Medical Mission Hills